keyword
MENU ▼
Read by QxMD icon Read
search

Cannabidiol

keyword
https://www.readbyqxmd.com/read/28088032/oral-cannabidiol-does-not-produce-a-signal-for-abuse-liability-in-frequent-marijuana-smokers
#1
Shanna Babalonis, Margaret Haney, Robert J Malcolm, Michelle R Lofwall, Victoria R Votaw, Steven Sparenborg, Sharon L Walsh
BACKGROUND: Cannabidiol (CBD) is a naturally occurring constituent of the marijuana plant. In the past few years, there has been great interest in the therapeutic effects of isolated CBD and it is currently being explored for numerous disease conditions (e.g., pain, epilepsy, cancer, various drug dependencies). However, CBD remains a Schedule I drug on the U.S. Controlled Substances Act (CSA). Despite its status, there are no well-controlled data available regarding its abuse liability...
December 14, 2016: Drug and Alcohol Dependence
https://www.readbyqxmd.com/read/28087250/pharmacology-of-cannabinoids-in-the-treatment-of-epilepsy
#2
REVIEW
Tyler E Gaston, Daniel Friedman
The use of cannabis products in the treatment of epilepsy has long been of interest to researchers and clinicians alike; however, until recently very little published data were available to support its use. This article summarizes the available scientific data of pharmacology from human and animal studies on the major cannabinoids which have been of interest in the treatment of epilepsy, including ∆9-tetrahydrocannabinol (∆9-THC), cannabidiol (CBD), ∆9-tetrahydrocannabivarin (∆9-THCV), cannabidivarin (CBDV), and ∆9-tetrahydrocannabinolic acid (Δ9-THCA)...
January 10, 2017: Epilepsy & Behavior: E&B
https://www.readbyqxmd.com/read/28069869/determination-of-%C3%A2-9-tetrahydrocannabinol-thc-11-hydroxy-thc-11-nor-9-carboxy-thc-and-cannabidiol-in-human-plasma-using-gas-chromatography-tandem-mass-spectrometry
#3
David M Andrenyak, David E Moody, Matthew H Slawson, Daniel S O'Leary, Margaret Haney
Two marijuana compounds of particular medical interest are delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD). A gas chromatography-tandem mass spectrometry (GC-MS-MS) method was developed to test for CBD, THC, hydroxy-THC (OH-THC) and carboxy-THC (COOH-THC) in human plasma. Calibrators (THC and OH-THC, 0.1 to 100; CBD, 0.25 to 100; COOH-THC, 0.5-500 ng/mL) and controls (0.3, 5 and 80 ng/mL, except COOH-THC at 1.5, 25 and 400 ng/mL) were prepared in blank matrix. Deuterated (d3) internal standards were added to 1-mL samples...
January 8, 2017: Journal of Analytical Toxicology
https://www.readbyqxmd.com/read/28043732/interactions-between-cannabidiol-and-%C3%AE-9-thc-following-acute-and-repeated-dosing-rebound-hyperactivity-sensorimotor-gating-and-epigenetic-and-neuroadaptive-changes-in-the-mesolimbic-pathway
#4
Stephanie M Todd, Cilla Zhou, David J Clarke, Tariq W Chohan, Dilara Bahceci, Jonathon C Arnold
The evidence base for the use of medical cannabis preparations containing specific ratios of cannabidiol (CBD) and Δ(9)-tetrahydrocannabinol (THC) is limited. While there is abundant data on acute interactions between CBD and THC, few studies have assessed the impact of their repeated co-administration. We previously reported that CBD inhibited or potentiated the acute effects of THC dependent on the measure being examined at a 1:1 CBD:THC dose ratio. Further, CBD decreased THC effects on brain regions involved in memory, anxiety and body temperature regulation...
December 30, 2016: European Neuropsychopharmacology: the Journal of the European College of Neuropsychopharmacology
https://www.readbyqxmd.com/read/28025562/cannabidiol-modulates-the-expression-of-alzheimer-s-disease-related-genes-in-mesenchymal-stem-cells
#5
Rosaliana Libro, Francesca Diomede, Domenico Scionti, Adriano Piattelli, Gianpaolo Grassi, Federica Pollastro, Placido Bramanti, Emanuela Mazzon, Oriana Trubiani
Mesenchymal stem cells (MSCs) have emerged as a promising tool for the treatment of several neurodegenerative disorders, including Alzheimer's disease (AD). The main neuropathological hallmarks of AD are senile plaques, composed of amyloid beta (Aβ), and neurofibrillary tangles, formed by hyperphosphorylated tau. However, current therapies for AD have shown limited efficacy. In this study, we evaluated whether pre-treatment with cannabidiol (CBD), at 5 μM concentration, modulated the transcriptional profile of MSCs derived from gingiva (GMSCs) in order to improve their therapeutic potential, by performing a transcriptomic analysis by the next-generation sequencing (NGS) platform...
December 23, 2016: International Journal of Molecular Sciences
https://www.readbyqxmd.com/read/28018227/bidirectional-effects-of-cannabidiol-on-contextual-fear-memory-extinction
#6
Chenchen Song, Carl W Stevenson, Francisco S Guimaraes, Jonathan L C Lee
Cannabidiol (CBD) has been established to have both acute and long-lasting effects to reduce fear memory expression. The long-lasting impact might be mediated by an enhancement of memory extinction or an impairment of memory reconsolidation. Here, we directly compared the effects of i.p. injections of cannabidiol (10 mg/kg) with those of the NMDA receptor antagonist MK-801 (0.1 mg/kg) and partial agonist D-cycloserine (DCS; 15 mg/kg) in order to determine the mnemonic basis of long-term fear reduction. We showed that under conditions of strong fear conditioning, CBD reduced contextual fear memory expression both acutely during the extinction session as well as later at a fear retention test...
2016: Frontiers in Pharmacology
https://www.readbyqxmd.com/read/28013001/mitochondrial-functions-of-thp-1-monocytes-following-the-exposure-to-selected-natural-compounds
#7
Nadin Schultze, Heike Wanka, Paula Zwicker, Ulrike Lindequist, Beate Haertel
The immune system is an important target of various xenobiotics, which may lead to severe adverse effects including immunosuppression or inappropriate immunostimulation. Mitochondrial toxicity is one possibility by which xenobiotics exert their toxic effects in cells or organs. In this study, we investigated the impact of three natural compounds, cyclosporine A (CsA), deoxynivalenol (DON) and cannabidiol (CBD) on mitochondrial functions in the THP-1 monocytic cell line. The cells were exposed for 24h to two different concentrations (IC10 and IC50 determined by MTT) of each compound...
December 21, 2016: Toxicology
https://www.readbyqxmd.com/read/28012949/cannabidiol-reduces-brain-damage-and-improves-functional-recovery-in-a-neonatal-rat-model-of-arterial-ischemic-stroke
#8
Maria Ceprián, Laura Jiménez-Sánchez, Carlos Vargas, Lorena Barata, Will Hind, Jose Martínez-Orgado
BACKGROUND: and purpose: Currently there is no effective treatment for neonatal arterial ischemic stroke (AIS). Cannabidiol (CBD) is neuroprotective in models of newborn hypoxic-ischemic brain damage and adult stroke. The purpose of this work was to study the protective effect of CBD in a neonatal rat model of AIS. METHODS: Middle Cerebral Artery Occlusion (MCAO) was achieved in neonatal Wistar rats by introducing a nylon filament to the left MCA for 3 h; 15 min after removing the occluder vehicle (MCAO-V) or CBD single dose 5 mg/kg (MCAO-C) were administered i...
December 21, 2016: Neuropharmacology
https://www.readbyqxmd.com/read/27989385/cannabis-and-epilepsy-an-ancient-treatment-returns-to-the-fore
#9
REVIEW
Ethan B Russo
Cannabis has been associated with the treatment of epilepsy throughout history, and if ancient Assyrian sources referring to "hand of ghost" are considered credible, this relationship may span four millennia. A tradition of usage continued in Arabic medicine and Ayurvedic practice in India, which led, in turn, to early experiments in Europe and North America with "Indian hemp." Lack of standardization, bioavailability issues, and ultimately prohibition were all factors in cannabis-based medicines failing to maintain mainstream usage in seizure treatment, but investigation was resumed in the 1970s with interesting signals noted in both laboratory and clinical settings...
December 15, 2016: Epilepsy & Behavior: E&B
https://www.readbyqxmd.com/read/27976061/inhibition-of-cervical-cancer-cell-proliferation-by-cannabidiol
#10
P Bagavandoss, B Crawford, C Kramer
No abstract text is available yet for this article.
December 2016: Planta Medica
https://www.readbyqxmd.com/read/27956834/an-observational-postmarketing-safety-registry-of-patients-in-the-uk-germany-and-switzerland-who-have-been-prescribed-sativex-%C3%A2-thc-cbd-nabiximols-oromucosal-spray
#11
Tilden Etges, Kari Karolia, Thomas Grint, Adam Taylor, Heather Lauder, Brian Daka, Stephen Wright
The global exposure of Sativex(®) (Δ(9)-tetrahydrocannabinol [THC]:cannabidiol [CBD], nabiximols) is estimated to be above 45,000 patient-years since it was given marketing approval for treating treatment-resistant spasticity in multiple sclerosis (MS). An observational registry to collect safety data from patients receiving THC:CBD was set up following its approval in the UK, Germany, and Switzerland, with the aim of determining its long-term safety in clinical practice. Twice a year, the Registry was opened to prescribing physicians to voluntarily report data on patients' use of THC:CBD, clinically significant adverse events (AEs), and special interest events...
2016: Therapeutics and Clinical Risk Management
https://www.readbyqxmd.com/read/27932991/cannabidiol-modulates-the-immunophenotype-and-inhibits-the-activation-of-the-inflammasome-in-human-gingival-mesenchymal-stem-cells
#12
Rosaliana Libro, Domenico Scionti, Francesca Diomede, Marco Marchisio, Gianpaolo Grassi, Federica Pollastro, Adriano Piattelli, Placido Bramanti, Emanuela Mazzon, Oriana Trubiani
Human Gingival Mesenchymal Stem Cells (hGMSCs) are multipotential cells that can expand and differentiate in culture under specific and standardized conditions. In the present study, we have investigated whether in vitro pre-treatment of hGMSCs with Cannabidiol (CBD) can influence their expression profile, improving the therapeutic potential of this cell culture. Following CBD treatment (5 μM) for 24 h, gene expression analysis through Next Generation Sequencing (NGS) has revealed several genes differentially expressed between CBD-treated hGMSCs (CBD-hGMSCs) and control cells (CTR-hGMSCs) that were linked to inflammation and apoptosis...
2016: Frontiers in Physiology
https://www.readbyqxmd.com/read/27932983/cannabidiol-regulation-of-learned-fear-implications-for-treating-anxiety-related-disorders
#13
Regimantas Jurkus, Harriet L L Day, Francisco S Guimarães, Jonathan L C Lee, Leandro J Bertoglio, Carl W Stevenson
Anxiety and trauma-related disorders are psychiatric diseases with a lifetime prevalence of up to 25%. Phobias and post-traumatic stress disorder (PTSD) are characterized by abnormal and persistent memories of fear-related contexts and cues. The effects of psychological treatments such as exposure therapy are often only temporary and medications can be ineffective and have adverse side effects. Growing evidence from human and animal studies indicates that cannabidiol, the main non-psychotomimetic phytocannabinoid present in Cannabis sativa, alleviates anxiety in paradigms assessing innate fear...
2016: Frontiers in Pharmacology
https://www.readbyqxmd.com/read/27918106/cannabidiol-activates-neuronal-precursor-genes-in-human-gingival-mesenchymal-stromal-cells
#14
Thangavelu Soundara Rajan, Sabrina Giacoppo, Domenico Scionti, Francesca Diomede, Gianpaolo Grassi, Federica Pollastro, Adriano Piattelli, Placido Bramanti, Emanuela Mazzon, Oriana Trubiani
In the last years, mesenchymal stromal cells (MSCs) from oral tissues have received considerable interest in regenerative medicine since they can be obtained with minimal invasive procedure and exhibit immunomodulatory properties. This study was aimed to investigate whether in vitro pre-treatment of MSCs obtained from human gingiva (hGMSCs) with Cannabidiol (CBD), a cannabinoid component produced by the plant Cannabis sativa, may promote human gingiva derived MSCs to differentiate toward neuronal precursor cells...
December 5, 2016: Journal of Cellular Biochemistry
https://www.readbyqxmd.com/read/27899456/free-and-glucuronide-whole-blood-cannabinoids-pharmacokinetics-after-controlled-smoked-vaporized-and-oral-cannabis-administration-in-frequent-and-occasional-cannabis-users-identification-of-recent-cannabis-intake
#15
Matthew N Newmeyer, Madeleine J Swortwood, Allan J Barnes, Osama A Abulseoud, Karl B Scheidweiler, Marilyn A Huestis
BACKGROUND: There is increasing interest in markers of recent cannabis use because following frequent cannabis intake, Δ(9)-tetrahydrocannabinol (THC) may be detected in blood for up to 30 days. The minor cannabinoids cannabidiol, cannabinol (CBN), and THC-glucuronide were previously detected for ≤2.1 h in frequent and occasional smokers' blood after cannabis smoking. Cannabigerol (CBG), Δ(9)-tetrahydrocannabivarin (THCV), and 11-nor-9-carboxy-THCV might also be recent use markers, but their blood pharmacokinetics have not been investigated...
December 2016: Clinical Chemistry
https://www.readbyqxmd.com/read/27890794/target-regulation-of-pi3k-akt-mtor-pathway-by-cannabidiol-in-treatment-of-experimental-multiple-sclerosis
#16
Sabrina Giacoppo, Federica Pollastro, Gianpaolo Grassi, Placido Bramanti, Emanuela Mazzon
This study was aimed to investigate whether treatment with purified cannabidiol (CBD) may counteract the development of experimental multiple sclerosis (MS), by targeting the PI3K/Akt/mTOR pathway. Although the PI3K/Akt/mTOR pathway was found to be activated by cannabinoids in several immune and non-immune cells, currently, there is no data about the effects of CBD in the PI3K/Akt/mTOR activity in MS. Experimental Autoimmune Encephalomyelitis (EAE), the most common model of MS, was induced in C57BL/6 mice by immunization with myelin oligodendroglial glycoprotein peptide (MOG)35-55...
January 2017: Fitoterapia
https://www.readbyqxmd.com/read/27889412/cannabidiol-reduces-neuroinflammation-and-promotes-neuroplasticity-and-functional-recovery-after-brain-ischemia
#17
Marco Aurélio Mori, Erika Meyer, Ligia Mendes Soares, Humberto Milani, Francisco Silveira Guimarães, Rúbia Maria Weffort de Oliveira
This study investigated the effects of cannabidiol (CBD), a non-psychotomimetic phytochemical present in Cannabis sativa, on the cognitive and emotional impairments induced by bilateral common carotid artery occlusion (BCCAO) in mice. Using a multi-tiered behavioral testing battery during 21days, we found that BCCAO mice exhibited long-lasting functional deficits reflected by increase in anxiety-like behavior (day 9), memory impairments (days 12-18) and despair-like behavior (day 21). Short-term CBD 10mg/kg treatment prevented the cognitive and emotional impairments, attenuated hippocampal neurodegeneration and white matter (WM) injury, and reduced glial response that were induced by BCCAO...
November 23, 2016: Progress in Neuro-psychopharmacology & Biological Psychiatry
https://www.readbyqxmd.com/read/27884751/a-systematic-review-of-the-effect-of-cannabidiol-on-cognitive-function-relevance-to-schizophrenia
#18
REVIEW
Ashleigh L Osborne, Nadia Solowij, Katrina Weston-Green
BACKGROUND AND OBJECTIVES: Cognitive impairment is a core symptom domain of schizophrenia, neurological disorders and substance abuse. It is characterised by deficits in learning, memory, attention and executive functioning and can severely impact daily living. Antipsychotic drugs prescribed to treat schizophrenia provide limited cognitive benefits and novel therapeutic targets are required. Cannabidiol (CBD), a component of the cannabis plant, has anti-inflammatory and antipsychotic-like properties; however, its ability to improve cognitive impairment has not been thoroughly explored...
January 2017: Neuroscience and Biobehavioral Reviews
https://www.readbyqxmd.com/read/27877130/cannabidiol-as-a-potential-new-type-of-an-antipsychotic-a-critical-review-of-the-evidence
#19
REVIEW
Cathrin Rohleder, Juliane K Müller, Bettina Lange, F M Leweke
There is urgent need for the development of mechanistically different and less side-effect prone antipsychotic compounds. The endocannabinoid system has been suggested to represent a potential new target in this indication. While the chronic use of cannabis itself has been considered a risk factor contributing to the development of schizophrenia, triggered by the phytocannabinoid delta-9-tetrahydrocannabinol (Δ(9)-THC), cannabidiol, the second most important phytocannabinoid, appears to have no psychotomimetic potential...
2016: Frontiers in Pharmacology
https://www.readbyqxmd.com/read/27874495/evolution-of-multiple-sclerosis-spasticity-associated-symptoms-latest-data
#20
Peter Flachenecker
In addition to muscle stiffness and increasing mobility restrictions, symptoms commonly associated with multiple sclerosis (MS) spasticity are spasms, sleep disturbances, pain, fatigue and bladder dysfunction. Treatment options include trigger factor avoidance, physiotherapy and antispasticity medication. Oral antispasticity agents commonly used in Germany are baclofen, tizanidine and gabapentin, but physician and patient satisfaction with their effectiveness is low. Over the past few years, randomized controlled trials, observational studies and registry data have demonstrated the positive risk:benefit profile of add-on 9-delta-tetra-hydrocannabinol:cannabidiol oromucosal spray for moderate-to-severe resistant MS spasticity...
December 2016: Neurodegenerative Disease Management
keyword
keyword
1686
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"